The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.
The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.
A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.
The consortium, which spans more than a dozen UK cities, will sequence patient samples to understand the spread and evolution of the novel coronavirus.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
